Androgen replacement and/or 5 alpha reductase inhibitors in aging men
Klotz, L.H.
Canadian Journal of Urology 13(Suppl 1): 44-45
2006
ISSN/ISBN: 1195-9479 PMID: 16526981 Document Number: 598480
A case study of a typical 65 year old man with symptoms of both LUTS with established BPH, and andropause, is presented. The case for 5ARI therapy versus androgen replacement therapy is discussed, and the evidence for the use of these drugs in combination is reviewed.
Document emailed within 1 workday
Related Documents
Azzouni, F.; Zeitouni, N.; Mohler, J. 2013: Role of 5α-reductase inhibitors in androgen-stimulated skin disorders Journal of Drugs in Dermatology: Jdd 12(2): E30-E35Reichardt, J.K. 2000: Prostatic steroid 5 alpha-reductase, an androgen metabolic gene Mayo Clinic Proceedings 75 Suppl: S36-S39
2003: 5-alpha reductase inhibitors plus alpha blockers. A combination therapy keeps a common disease checked MMW Fortschritte der Medizin 145(27-28): 58-59
Raynor, M.C.; Carson, C.C.; Pearson, M.D.; Nix, J.W. 2007: Androgen deficiency in the aging male: a guide to diagnosis and testosterone replacement therapy Canadian Journal of Urology 14(Suppl 1): 63-68
Batzold, F.H. 1981: Approaches to prostatic 5 alpha-reductase inhibitors Progress in Clinical and Biological Research 75b: 269-282
Djavan, B.; McConnell, J. 1996: The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia Wiener Medizinische Wochenschrift 146(8): 165-168
Jaworska, L.; Rembiesa, R. 1982: Effect of delta 4-5 alpha-reductase inhibitors on progesterone 4-C-14 metabolism in the rat placenta in vitro Endokrynologia Polska 33(4-6): 183-191
Cohen, J.; Ooms, M.P.; Vreeburg, J.T. 1981: Reduction of fertilizing capacity of epididymal spermatozoa by 5 alpha-steroid reductase inhibitors Experientia 37(9): 1031-1032
Wu, J-Hui.; Sun, Z-Yue. 2013: Establishment of an in vitro screening model for steroid 5 alpha-reductase inhibitors with the microplate reader Zhonghua Nan Ke Xue 19(6): 483-486
Sun, Z.Y.; Tu, Z.H. 1998: A novel in vitro model to screen steroid 5 alpha-reductase inhibitors against benign prostatic hyperplasia Methods and Findings in Experimental and Clinical Pharmacology 20(4): 283-287
Reyes, E.F.; Virgo, B.B. 1988: Neonatal programming of ethylmorphine demethylase and corticosteroid 5 alpha-reductase by testosterone, dihydrotestosterone, and estradiol. Effects of an anti-estrogen, an anti-androgen, and an inhibitor of estrogen synthetase Drug Metabolism and Disposition: the Biological Fate of Chemicals 16(1): 93-97
Schicker, I. 2000: Sports or hormones for aging men? when Adam suffers from PADAM (partial androgen deficit of the aging man) MMW Fortschritte der Medizin 142(35): 12-13
Akishita, M. 2007: Hormone replacement Up-to-date. Effects of androgen replacement therapy on vascular function and atherosclerosis Clinical Calcium 17(9): 1385-1391
Yamamoto, A. 2001: HMG-CoA reductase inhibitors Nihon Rinsho. Japanese Journal of Clinical Medicine 59(Suppl 3): 578-586
Tomita, N.; Morishita, R.; Ogihara, T. 2002: Pharmacological effects of HMG-CoA reductase inhibitors Nihon Rinsho. Japanese Journal of Clinical Medicine 60(5): 955-961
Davignon, J.; Montigny, M.; Dufour, R. 1992: HMG-CoA reductase inhibitors: a look back and a look ahead Canadian Journal of Cardiology 8(8): 843-864
Morton, A.P. 2004: Androgen deficiency and replacement therapy in men Medical Journal of Australia 181(5): 286; Author Reply 286-7
Erkelens, D.W.; Bravenboer, B. 1990: Aldose reductase inhibitors in diabetic neuropathy Nederlands Tijdschrift Voor Geneeskunde 134(15): 775-776
Gmiński, J.; Wojakowski, W. 1997: Anti-atherosclerotic actions of HMG-CoA reductase inhibitors Przeglad Lekarski 54(11): 782-787
Fuentes, I.; Aguilera, C. 1998: Myopathy secondary to the treatment with inhibitors of HMG-CoA reductase Medicina Clinica 111(18): 700